The European Study of Altis Single Incision Sling System for Female Stress Urinary Incontinence

Stress Urinary Incontinence Clinical Trial

— EASY  

Official title:

The European Study of Altis Single Incision Sling System for Female Stress Urinary Incontinence

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02049840
• Other study ID #: SU016
• Status: Completed
• Phase: N/A
• Start date: December 16, 2013
• Est. completion date: July 21, 2021

Study information

• Verified date: September 2021
• Source: Coloplast A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, post-market, single arm, multicenter study comparing Baseline data to the 12 month and 36 month data in 136 female patients with Stress Urinary Incontinence

Description:

This study is a prospective, European Post-Market, one non-controlled arm, multi-centre clinical trial conducted at up to 10 centers in Europe. It is designed to get more clinical information for users (uro-gynecologists) of the Altis Single Incision Sling System for female stress urinary incontinence treatment in terms of objective and subjective cure rate, quality of life improvement, patient satisfaction and safety, especially in long term follow-up (3 years). Clinical data will be collected at baseline, implantation procedure, post-operative at 6 weeks, 6 months, 1, 2 and 3 years

Recruitment information / eligibility

• Status: Completed
• Enrollment: 153
• Est. completion date: July 21, 2021
• Est. primary completion date: November 4, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The subject is female at least 18 years of age

• The subject uses a method of contraception considered effective by the investigator or is not of child-bearing potential

• The subject is able and willing to complete all procedures and follow-up visits indicated in this protocol.

• The subject has confirmed stress urinary incontinence (SUI) through cough stress test at baseline.

• The subject has failed first line treatments (non-invasive therapies, eg. behavioral modification, Pelvic Floor/Kegel exercises, or biofeedback) with good compliance for the treatment

Exclusion Criteria:

• The subject had a prior surgical SUI treatment (including bulking agent).

• The subject is having a concomitant Pelvic Organ Prolapse repair or hysterectomy during Altis procedure.

• The subject has incontinence due to neurogenic causes (e.g. multiple sclerosis, spinal cord/brain injury, cerebrovascular accident, detrusor-external sphincter dyssynergia, Parkinson's disease, or similar conditions).

• The subject has predominant or uncontrolled or primary urge incontinence according to investigator judgment

• The patient has detrusor overactivity determined through urodynamics

• The subject has intrinsic sphincter deficiency defined urodynamically as a Maximal Urethral Closure Pressure < 20 cm H2O and/or Valsalva Leak Point Pressure < 60 cm H2O

• The subject has atonic bladder, a persistent post void residual (PVR) > 100 ml or chronic urinary retention.

• The subject has untreated urinary malignancy

• The subject has undergone radiation or brachy therapy or chemotherapy to treat pelvic cancer.

• The subject has urethrovaginal fistula or urethral diverticulum or congenital urinary anomalies

• The subject has serious bleeding disorder or requires anticoagulant therapy

• The subject is pregnant and/or is planning to get pregnant in the future.

• The subject has a Body Mass Index = 35 (obese class II).

• The subject has a contraindication to the surgical procedure according to the the Altis SIS System IFU.

• The subject has an active urogenital infection or active skin infection in region of surgery mainly at the time of implantation.

• The subject is enrolled in a concomitant clinical trial.

Related Conditions & MeSH terms

• Enuresis
• Stress Urinary Incontinence
• Urinary Incontinence
• Urinary Incontinence, Stress

Intervention

Device:
• Altis Single Incision Sling System
Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence

Locations

Country	Name	City	State
France	Hôpital Femme Mère Enfant	Bron
France	Hôpital de la Conception	Marseille
France	Centre Hospitalier Universitaire Carémeau	Nîmes
France	Centre Hospitalier Universitaire Carémeau - Gyneacology	Nîmes
France	Centre Hospitalier Universitaire de Rouen - Hôpital Charles Nicolle	Rouen
France	Nouvel Hôpital Civil	Strasbourg
Germany	Chirurgische Klinik München - Bogenhausen GmbH	München
Germany	Isarklinikum	München
Italy	Ospedale Garibaldi-Nesima	Catania
Netherlands	Isala Klinieken Locatie Sophia	Zwolle
Spain	Hospital Universitario La Ribera	Alcira	Valencia
Spain	Fundacion Jimenez Diaz	Madrid
Spain	Hospital de Sagunto	Sagunto	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Coloplast A/S

Countries where clinical trial is conducted

France,  Germany,  Italy,  Netherlands,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of subjects who meet the criteria of cure at 12 months	Cure is defined as negative Cough Stress Test (CST) and an answer "no" to question 3 "Do you usually experience urine leakage related to coughing, sneezing, or laughing?" of the UDI-6 questionnaire	1 year
Secondary	Proportion of subjects who have a negative cough stress test at each visit		6 weeks, 6 months, 1 year, 2 year, 3 year
Secondary	Proportion of subjects who meet the criteria of cure at each other visit	Cure is defined as negative Cough Stress Test (CST) and an answer "no" to question 3 "Do you usually experience urine leakage related to coughing, sneezing, or laughing?" of the UDI-6 questionnaire	6 weeks, 6 months, 2 year, 3 year
Secondary	Subject continence status measured by the 24-hour pad weight	The continence status will be described : Proportion of subjects who meet the criteria of dryness defined as a pad weight of less than 8 grams for the current practice Proportion of subjects who meet the criteria of improvement defined as at least a 50% reduction in pad weight from baseline	6 weeks, 1 year
Secondary	Assessment of self reported symptoms and subject QoL through the scoring of validated questionnaires: ICIQ-UI SF, I-QOL, UDI-6 and IIQ-7	The scores of ICIQ-UI short form, I-QOL, UDI-6 and IIQ-7 will be describe at each visit as continuous variables. The evolution of scores from baseline will be presented	6 weeks, 6 months, 1 year, 2 year, 3 year
Secondary	Postoperatively subject impression of improvement (via PGI-I questionnaire) and satisfaction at each post-operative visit		6 weeks, 6 months, 1 year, 2 year, 3 year
Secondary	Assessment of Qmax variations	Qmax (maximum flow rate in uroflowmetry section) raw value (at baseline, 6 weeks and 12 months) and absolute and relative variations from baseline et 6 weeks and 12 months will be described	6 weeks, 1year
Secondary	Assessment of PVR variations	PVR (Post void residual urine volume) raw value (at baseline, 6 weeks and 12 months) and absolute and relative variations from baseline et 6 weeks and 12 months will be described	6 weeks, 1 year
Secondary	Assessment of the operation duration and the type of anaesthesia used		Operative period
Secondary	Assessment of device and procedure related adverse events	All device or procedure related Adverse Events (AE) will be summarized and reported as the number and percentage of subjects having this AE and as the number and percentage of AE in Safety population.	Operative period, 6 weeks, 6 months, 1 year, 2 year, 3 year
Secondary	Assessment of postoperative pain	Visual Analogue Scale from 0 "no pain" to 10 "extreme pain"	operative period, 6 weeks, 6 months, 1 year